Integer (NYSE:ITGR) PT Raised to $145.00 at Bank of America

Integer (NYSE:ITGR) had its price target upped by Bank of America from $135.00 to $145.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Bank of America‘s price objective suggests a potential upside of 12.40% from the stock’s current price.

ITGR has been the subject of several other reports. Truist Financial increased their price target on Integer from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday. Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price objective for the company. Finally, Benchmark reiterated a “buy” rating and set a $130.00 price objective on shares of Integer in a report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Integer presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.43.

Integer Trading Down 0.8 %

NYSE:ITGR traded down $1.00 during mid-day trading on Tuesday, hitting $129.00. The company had a trading volume of 48,694 shares, compared to its average volume of 316,194. Integer has a fifty-two week low of $69.40 and a fifty-two week high of $131.87. The business’s fifty day moving average is $123.35 and its two-hundred day moving average is $119.22. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29. The firm has a market cap of $4.32 billion, a P/E ratio of 44.76, a P/E/G ratio of 1.87 and a beta of 1.09.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.06. Integer had a return on equity of 11.48% and a net margin of 6.31%. The company had revenue of $436.20 million during the quarter, compared to the consensus estimate of $437.00 million. During the same period in the prior year, the company earned $1.14 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. As a group, research analysts expect that Integer will post 5.31 earnings per share for the current year.

Insider Buying and Selling at Integer

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the completion of the transaction, the director now directly owns 2,280 shares in the company, valued at $272,824.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Integer

A number of hedge funds have recently made changes to their positions in ITGR. Quest Partners LLC lifted its position in shares of Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 142 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Integer during the 1st quarter worth approximately $106,000. Innealta Capital LLC acquired a new stake in Integer during the 2nd quarter worth approximately $110,000. Finally, Hancock Whitney Corp acquired a new stake in Integer during the 1st quarter worth approximately $203,000. 99.29% of the stock is owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.